Induction Agent Choice With Early Mortality and Prognostic Outcomes in Critically Ill Patients
NCT ID: NCT07222007
Last Updated: 2025-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
4 participants
OBSERVATIONAL
2026-01-02
2026-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Induction of Anesthesia With Sevoflurane Preserving Spontaneous Breathing: Cardiorespiratory Effects.
NCT04802122
Prospective Study of Induction Medications Used in the Trauma RSI
NCT04291521
Propofol Versus Sevoflurane for Induction of GA in Infants
NCT05105022
Analgesia-First Sedation in Trauma Patients
NCT05751863
Ketamine Versus Propofol as ICU Sedation
NCT06243822
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A recent international, multicentre, prospective cohort (INTUBE) study of 2964 critically ill patients undergoing tracheal intubation in the ICU, emergency department, or inpatient wards in 29 countries across five continents reported that the most frequently used agents for induction were Propofol (41.5%), Midazolam (36.4%), Etomidate (17.8%), and Ketamine (14.2%).
The choice of induction agent for intubation may have the potential to minimise or exacerbate complication and mortality. Although considerable research has been carried out, critical central question concern which induction agent is most effective in minimizing cardiovascular instability during intubation. As Kotani and Risotto declared in their recent systematic review, the available findings are insufficient to support conclusive statements. Further studies are needed to identify the optimal agent and dosage, taking into account patient variability and concurrent therapeutic interventions.
Understanding the impact of induction agent selection in critically ill patients has the potential to guide clinical practice in emergency and intensive care settings. Identifying agents with improved survival and prognosis would optimize patient management and inform decision-making for airway management in this vulnerable population. Moreover, delineating which agents exert minimal adverse effects on mortality and prognosis may provide valuable insight for anesthesiologists, intensivists, emergency medicine physicians, and trauma physicians.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
propofol
required induction of the following agent in ICU patient
induction type for intubation in ICU
Clinical data documented throughout the course of hospitalization will be retrieved and analyzed.
ketamine
required induction of the following agent in ICU patient
induction type for intubation in ICU
Clinical data documented throughout the course of hospitalization will be retrieved and analyzed.
ethomidate
required induction of the following agent in ICU patient
induction type for intubation in ICU
Clinical data documented throughout the course of hospitalization will be retrieved and analyzed.
midazolam
required induction of the following agent in ICU patient
induction type for intubation in ICU
Clinical data documented throughout the course of hospitalization will be retrieved and analyzed.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
induction type for intubation in ICU
Clinical data documented throughout the course of hospitalization will be retrieved and analyzed.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Admission to the surgical ICU for critical care
* Administration of one of the studied induction agents
* Availability of complete clinical data
Exclusion Criteria
* Absence of documented induction agent administration
* Incomplete or missing medical records
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Florida
OTHER
Zeliha Alicikus
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Zeliha Alicikus
Assoc. prof. dr
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
TOLGA SARAÇOĞLU, Prof,MD
Role: PRINCIPAL_INVESTIGATOR
Florida University Jacksonville
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UF Health Jacksonville (Shands Hospital)
Jacksonville, Florida, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
Tolga-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.